InvestSMART

Pacific Edge Limited (ASX: PEB) - Announcements

- Current share price for PEB : $0.220

ASX company news and announcements for Pacific Edge Limited (PEB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Pacific Edge Limited (PEB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Pacific Edge Limited (PEB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Pacific Edge Limited (PEB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$273 Director Nomination Closing Date 16 Jul 2024 7:30AM $0.078 $0.220 risen by 182.05%
$273 Application for quotation of securities - PEB 11 Jul 2024 1:26PM $0.078 $0.220 risen by 182.05%
$273 Notification regarding unquoted securities - PEB 11 Jul 2024 1:14PM $0.078 $0.220 risen by 182.05%
$273 Quarterly Update - Cxbladder Test Volumes Steady in Q1 25 10 Jul 2024 7:49AM $0.083 $0.220 risen by 165.06%
$273 Notification of cessation of securities - PEB 9 Jul 2024 2:56PM $0.081 $0.220 risen by 171.60%
$273 Annual Report 2024 27 Jun 2024 8:54AM $0.083 $0.220 risen by 165.06%
$273 Cash Burn Slows Coverage Catalysts in Focus 21 May 2024 7:31AM $0.085 $0.220 risen by 158.82%
$273 Becoming a substantial holder 1 May 2024 4:15PM $0.080 $0.220 risen by 175%
$273 Ceasing to be a substantial holder 1 May 2024 1:17PM $0.080 $0.220 risen by 175%
$273 Pacific Edge Full Year Result to be Announced 21 May 2024 1 May 2024 7:31AM $0.076 $0.220 risen by 189.47%
$273 Clinical Utility of Cxbladder to Headline at AUA 2024 30 Apr 2024 11:57AM $0.076 $0.220 risen by 189.47%
$273 Quarterly Update - Cxbladder Test Volumes Steady in Q4 24 9 Apr 2024 7:30AM $0.078 $0.220 risen by 182.05%
$273 Pacific Edge Directors Give Notice of Retirement 14 Mar 2024 7:31AM $0.087 $0.220 risen by 152.87%
$273 Cxbladder Test Volumes Correction 22 Jan 2024 2:44PM $0.100 $0.220 risen by 120%
$273 Quarterly Update - Test Volumes Fall Following Restructure 22 Jan 2024 8:22AM $0.100 $0.220 risen by 120%
$273 Application for quotation of securities - PEB 15 Dec 2023 11:28AM $0.075 $0.220 risen by 193.33%
$273 Change in substantial holding 5 Dec 2023 1:47PM $0.090 $0.220 risen by 144.44%
$273 Financial Results for the Half Year to 30 September 2023 23 Nov 2023 7:30AM $0.098 $0.220 risen by 124.49%
$273 Kaiser Permanente EMR Integration goes live 15 Nov 2023 7:30AM $0.095 $0.220 risen by 131.58%
$273 Notification regarding unquoted securities - PEB 25 Oct 2023 1:58PM $0.091 $0.220 risen by 141.76%
$273 NZX - D&O Disclosures - P Meintjes & G Gibson - 25 Oct 23 25 Oct 2023 1:41PM $0.091 $0.220 risen by 141.76%
$273 NZX - Capital Change Notice 25 Oct 2023 1:38PM $0.091 $0.220 risen by 141.76%
$273 Interim Financial Result to be Announced 23 November 2023 19 Oct 2023 7:30AM $0.100 $0.220 risen by 120%
$273 Notification of cessation of securities - PEB 16 Oct 2023 2:28PM $0.100 $0.220 risen by 120%
$273 Quarterly Update - Q2 24 Cxbladder Test Volumes Resilient 11 Oct 2023 7:48AM $0.100 $0.220 risen by 120%

126 - 150 of 261 results

Page 6 of 11

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.